Complement Therapeutics

Screening patient for AMD
#AMD #Complement Therapeutics #FDA #Geographic atrophy

FDA fast tracks geographic atrophy treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for a treatment for  geographic atrophy (GA) secondary to age-related macular degeneration (AMD).  CTx001, developed by biotechnology company Complement Therapeutics, is a novel adeno-associated virus (AAV)-based gene therapy designed… Read More

#News #Regulatory

Screening patient for AMD
#AMD #Clinical trial #Complement Therapeutics #FDA #Gene therapy #Geographic atrophy #Ophthalmology

FDA clears gene therapy trial in geographic atrophy

The US Food and Drug Administration (FDA) has cleared Complement Therapeutics’ Investigational New Drug (IND) application for CTx001, the company’s lead gene therapy candidate.   The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in patients with geographic atrophy (GA) secondary to age-related macular degeneration… Read More

#News #Regulatory

Screening patient for AMD
#Clinical research #Complement Therapeutics #Dry AMD #Gene therapy #Geographic atrophy #Ophthalmology

Non-interventional geographic atrophy study launches

Complement Therapeutics (CTx) has enrolled the first patient in its study of people diagnosed with geographic atrophy (GA).  The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future… Read More

#News

#Complement Therapeutics #Dry AMD #Gene therapy #Geographic atrophy #Scientific Advisory Board

Complement Therapeutics announces SAB to drive pipeline

Biotechnology company Complement Therapeutics (CTx) has formed a Clinical & Scientific Advisory Board to help accelerate the development of its pipeline of therapeutics targeting complement-mediated diseases. The company’s lead investigational product, CTx001, is a gene therapy for dry age-related macular degeneration/geographic atrophy, which is a leading cause of blindness. The… Read More

#News